Five women in Rajasthan seeking help after alleged postpartum kidney failure have drawn attention to postpartum acute kidney ...

Dimerix Limited (ASX: DXB, "Dimerix") a clinical-stage biopharmaceutical company developing kidney disease treatments, is pleased to announce that it has acquired DMX-652 for all indications from ...

Sponsors educational summit of leading pediatric AKI health care experts Announces best practices webinar to further advance new treatment ...

Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to ASX-listed renal specialist ...

Mission Therapeutics has agreed to divest its phase 2‑ready acute kidney injury candidate MTX652 to Australian renal ...

A recent study published in the Journal of the American Medical Association revealed that acute kidney injury (AKI) in ...

Mission Therapeutics has announced that MTX652, its Phase 2-ready USP30 inhibitor for acute kidney injury, has been acquired by Australian Stock Exchange-listed renal specialist Dimerix in a ...

Five women from Rajasthan's Kota suffering from postpartum kidney failure have refused to continue dialysis and intensified ...

CT angiography of the abdomen showed occlusion of the proximal left main renal artery with global hypoperfusion of the left kidney (arrow). A ...

Increases in serum creatinine similar to patients who received usual care ...

Renal ischaemia–reperfusion injury (RIRI) arises when blood flow to the kidney is interrupted and then restored, triggering a cascade of cellular and molecular events that culminate in acute kidney ...